echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The clinical trial application of ASK0912 for injection, a subsidiary of Osaikang, was accepted

    The clinical trial application of ASK0912 for injection, a subsidiary of Osaikang, was accepted

    • Last Update: 2022-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 16, 2022, Osaikang issued an announcement stating that Jiangsu Osaikang Injection ASK0912, a wholly-owned subsidiary of the company, recently received the "Notice of Acceptance" for the application for new drug clinical trials issued by the NMPA


    ASK0912 is a class 1 innovative drug project jointly developed by the Institute of Medical Biotechnology, Chinese Academy of Medical Sciences and Jiangsu Osaikang.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.